FDA Approves Drug with New Mechanism of Action for …
Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults.
3 Things to Know About Cobenfy, the New Schizophrenia Drug
2 days ago · Cobenfy is the first of what could potentially be several new medications that target receptors in the brain other than dopamine. Similar drugs are still in or may soon be in clinical testing phases. Cobenfy, which comes in a single capsule, is a combination of two drugs: xanomeline and trospium chloride. Xanomeline was tested in the late 1990s ...
A new kind of drug for schizophrenia promises fewer side effects
Sep 27, 2024 · A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to schizophrenia treatment. The Food and Drug Administration approved it Thursday.
FDA approves Cobenfy, a brand new type of schizophrenia drug : …
Oct 23, 2024 · Cobenfy, a new drug made by Bristol Myers Squibb and approved by the FDA last week, triggers muscarinic receptors instead of dopamine receptors. It's the first schizophrenia treatment to do so.
Cobenfy: The First New Schizophrenia Drug in Decades
Oct 2, 2024 · The FDA has approved Cobenfy, the first new schizophrenia treatment in over 30 years. Cobenfy helps reduce both positive and negative schizophrenia symptoms, with side effects compared to current medications.
FDA Approves the First New Schizophrenia Drug in Decades
Sep 27, 2024 · N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the...
FDA Approves Revolutionary Schizophrenia Drug - WebMD
Sept. 27, 2024 – In a breakthrough for people living with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be...
Schizophrenia drug KarXT wins FDA approval - USA TODAY
Sep 26, 2024 · Studies showed Bristol Myers Squibb's drug, KarXT, improved symptoms of schizophrenia and led to fewer side effects than existing antipsychotic treatments.
Breakthrough treatment for schizophrenia | News | Wellcome
Sep 27, 2024 · Now, a new combination drug called Cobenfy has been approved by the US Food and Drug Administration (FDA). It is the first new pharmacological approach for treating schizophrenia in over 50 years and may provide an alternative …
A New Drug Compound Shows Promise for Schizophrenia
Dec 15, 2023 · KarXT, developed by biotech company Karuna Therapeutics, targets a different brain chemical than most existing schizophrenia treatments and appears to have fewer side effects.